
EASD 2025: Spotlight on Orforglipron, Cardiovascular Potential, and Beyond
EASD 2025: Orforglipron in Focus, the Case for Cardiovascular Benefits, More While Eli Lilly’s orforglipron is top of mind heading into the European Association for the Study of Diabetes meeting…












